Navigation Links
St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
Date:9/7/2010

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

The five-year, $8.6 million grant is titled "PAAR4KidsPharmacogenomics of Anticancer Agents Research in Children."

"We've been part of the PGRN for 10 years. But now, we will be the only PGRN group to focus on children, and we are partnering with NCI's Children's Oncology Group. We will be able to comprehensively study children with acute lymphoblastic leukemia, and we are moving some pharmacogenetic testing into real patient care," said Mary V. Relling, Pharm.D., Pharmaceutical Sciences chair at St. Jude.

A scientist at St. Jude since 1988, Relling's research focuses on pharmacokinetics and pharmacodynamics in children and how genome variability influences response to cancer chemotherapy.

In support of personalized medicine, the NIH has expanded the PGRN, a nationwide group of scientists focused on understanding how genes affect a person's response to medicines. The NIH estimates it will spend $161.3 million over the next five years to expand the network.

Spearheaded by the NIH's National Institute of General Medical Sciences (NIGMS) and launched in 2000, the PGRN has already identified gene variants linked to people's responses to medicines for cancer, heart disease, asthma, nicotine addiction and other conditions. The PGRN projects beginning this summer will build on this decade-old foundation and move the PGRN into several new areas: rheumatoid arthritis, bipolar disorder, and rural and underserved populations.

Along with St. Jude, the other PGRN research groups include University of California, San Francisco; University of Florida, Gainesville; University of California, San Diego; Children's Hospital Oakland Research Institute, Calif.; University of Pennsylvania, Philadelphia; University of Toronto; Brigham and Women's Hospital, Boston, Mass.; The University of Chicago, Ill.; Vanderbilt University School of Medicine, Nashville, Tenn.; The Ohio State University, Columbus; University of Maryland, Baltimore; University of Washington, Seattle; and Mayo Clinic, Rochester, Minn.

PAAR4Kids is funded by three NIH components: NIGMS, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Cancer Institute. Other NIH components funding the PGRN include the National Heart, Lung, and Blood Institute; the National Institute on Drug Abuse; the National Human Genome Research Institute; the National Institute of Mental Health; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and the Office of Research on Women's Health in the Office of the Director.

The project described was supported by Award Number U01GM092666 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.


'/>"/>

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: